This HTML5 document contains 81 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/company/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00308/identifier/wikipedia/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00308/identifier/pharmgkb/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00308/identifier/kegg-compound/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00308/identifier/bindingdb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00308/identifier/pubchem-compound/
n26http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00308/identifier/pubchem-substance/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00308/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00308/identifier/drugbank/
n15http://www.rxlist.com/cgi/generic/
n6http://linked.opendata.cz/resource/drugbank/patent/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
n17http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n30http://linked.opendata.cz/resource/drugbank/drug/DB00308/identifier/national-drug-code-directory/
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00308/identifier/chemspider/
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00308
rdf:type
n3:Drug
n3:description
Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. [Wikipedia]
n3:dosage
n21:271B4F64-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
6 hours (ranges from 2-12 hours)
n3:indication
Indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.
n3:manufacturer
n8:271B4F5F-363D-11E5-9242-09173F13E4C5 n8:271B4F60-363D-11E5-9242-09173F13E4C5 n8:271B4F61-363D-11E5-9242-09173F13E4C5
owl:sameAs
n23:DB00308 n26:DB00308
dcterms:title
Ibutilide
adms:identifier
n12:46507904 n13:60753 n19:PA449958 n24:54755 n25:DB00308 n27:50131432 n28:Ibutilide n29:D00648 n30:0574-0840-01 n31:C07753
n3:mechanismOfAction
Ibutilide is a 'pure' class III antiarrhythmic drug, used intravenously against atrial flutter and fibrillation. At a cellular level it exerts two main actions: induction of a persistent Na+ current sensitive to dihydropyridine Ca<sup>2+</sup> channel blockers and potent inhibition of the cardiac rapid delayed rectifier K<sup>+</sup> current, by binding within potassium channel pores. In other words, Ibutilide binds to and alters the activity of hERG potassium channels, delayed inward rectifier potassium (IKr) channels and L-type (dihydropyridine sensitive) calcium channels
n3:packager
n8:271B4F5E-363D-11E5-9242-09173F13E4C5 n8:271B4F5C-363D-11E5-9242-09173F13E4C5 n8:271B4F5D-363D-11E5-9242-09173F13E4C5 n8:271B4F5B-363D-11E5-9242-09173F13E4C5
n3:patent
n6:5155268
n3:routeOfElimination
In healthy male volunteers, about 82% of a 0.01 mg/kg dose of [14C] ibutilide fumarate was excreted in the urine (about 7% of the dose as unchanged ibutilide) and the remainder (about 19%) was recovered in the feces.
n3:synonym
Ibutilida N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamide Ibutilide Corvert Ibutilide Fumarate Ibutilidum Ibutilid
n3:toxicity
Acute overdose in animals results in CNS toxicity; notably, CNS depression, rapid gasping breathing, and convulsions. The intravenous median lethal dose in the rat was more than 50 mg/kg which is, on a mg/m<sup>2</sup> basis, at least 250 times the maximum recommended human dose.
n3:volumeOfDistribution
* 11 L/kg
n9:hasAHFSCode
n20:24-04-04-20
n3:proteinBinding
40%
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Ibutilide.htm
n17:hasConcept
n18:M0184268
foaf:page
n15:ibutilide.htm n16:ibutilide.html
n3:IUPAC-Name
n4:271B4F69-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4F6F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4F6E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4F6B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4F6C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4F6D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4F67-363D-11E5-9242-09173F13E4C5 n4:271B4F7F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4F65-363D-11E5-9242-09173F13E4C5 n4:271B4F68-363D-11E5-9242-09173F13E4C5 n4:271B4F80-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4F66-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:C01BD05
n3:H-Bond-Acceptor-Count
n4:271B4F75-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4F76-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4F70-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4F71-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4F73-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4F72-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4F74-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapid after intravenous injection
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
122647-32-9
n3:category
n3:clearance
* 29 mL/min/kg
n3:containedIn
n5:271B4F62-363D-11E5-9242-09173F13E4C5 n5:271B4F63-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4F7B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4F7D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4F7E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4F7A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4F79-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4F7C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4F6A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4F77-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4F78-363D-11E5-9242-09173F13E4C5